Literature DB >> 18224467

Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan.

Yasuhiro Ito1, Mitsuyoshi Hirokawa, Mitsuhiro Fukushima, Hiroyuki Inoue, Tomonori Yabuta, Takashi Uruno, Minoru Kihara, Takuya Higashiyama, Yuuki Takamura, Akihiro Miya, Kaoru Kobayashi, Fumio Matsuzuka, Akira Miyauchi.   

Abstract

BACKGROUND: In the 1980s, histology of a poorly differentiated carcinoma showing an aggressive behavior was proposed by Sakamoto et al. and other pathologists. This was adopted as an independent entity by the World Health Organization (WHO) and in the General Rules for the Description of Thyroid Cancer by The Japanese Society of Thyroid Surgery (JSTS). Furthermore, the Turin classification was recently proposed as the newest classification system for poorly differentiated carcinoma. Furthermore, although tall cell variant is not included in poorly differentiated carcinoma, it is thought to show aggressive characteristics. In this study, we investigated the prevalence and clinical significance of three types of poorly differentiated carcinoma defined by the WHO classification system (poorly differentiated carcinoma [WHO]), Turin proposal (poorly differentiated carcinoma [Turin]), and JSTS (poorly differentiated carcinoma [Sakamoto]), and tall cell variant in papillary carcinoma.
METHODS: We investigated the prevalence and prognostic significance of these three histological types in 1707 papillary carcinomas.
RESULTS: In our series, 189 (11.1%), 15 (0.8%), 5 (0.3%), and 62 (3.6%) patients were diagnosed as having poorly differentiated carcinoma (Sakamoto), poorly differentiated carcinoma (WHO), poorly differentiated carcinoma (Turin), and tall cell variant, respectively. Poorly differentiated carcinoma (WHO) and tall cell variant independently affected cause-specific survival (CSS) of patients, but poorly differentiated carcinoma (Sakamoto) predicted only worse disease-free survival (DFS) of patients on multivariate analysis. Poorly differentiated carcinoma (Turin) showed the worst DFS and CSS rates of patients but was not confirmed as an independent prognostic factor probably because of the small number of patients.
CONCLUSIONS: Poorly differentiated carcinoma (WHO) and tall cell variant significantly affected patient prognosis. Poorly differentiated carcinoma (Turin) accounts only for 0.3% but showed the worst survival rates. Although poorly differentiated carcinoma (Sakamoto) predicted the likelihood of carcinoma recurrence, it is more appropriate to define this lesion as one of the histological subtypes of papillary carcinoma rather than as an independent histological entity.

Entities:  

Mesh:

Year:  2008        PMID: 18224467     DOI: 10.1007/s00268-007-9406-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  19 in total

1.  Poorly differentiated thyroid carcinoma--it is important.

Authors:  L A Akslen; V A LiVolsi
Journal:  Am J Surg Pathol       Date:  2000-02       Impact factor: 6.394

Review 2.  Poorly differentiated thyroid carcinoma: introduction to the issue, its landmarks, and clinical impact.

Authors:  Juan Rosai
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

3.  Genome-wide appraisal of thyroid cancer progression.

Authors:  Volkert B Wreesmann; Ronald A Ghossein; Snehal G Patel; Charles P Harris; Erik A Schnaser; Ashok R Shaha; R Michael Tuttle; Jatin P Shah; Pulivarthi H Rao; Bhuvanesh Singh
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

4.  Prognostic implications of the tall cell variant of papillary thyroid carcinoma.

Authors:  T L Johnson; R V Lloyd; N W Thompson; W H Beierwaltes; J C Sisson
Journal:  Am J Surg Pathol       Date:  1988-01       Impact factor: 6.394

Review 5.  Definition of poorly differentiated carcinoma of the thyroid: the Japanese experience.

Authors:  Atsuhiko Sakamoto
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

6.  Another dissertation on poorly differentiated carcinomas: is it really necessary?

Authors:  R H Nishiyama
Journal:  Adv Anat Pathol       Date:  1999-09       Impact factor: 3.875

7.  Prognostic value of the tall cell variety of papillary cancer of the thyroid.

Authors:  A Moreno Egea; J M Rodriguez Gonzalez; J Sola Perez; T Soria Cogollos; P Parrilla Paricio
Journal:  Eur J Surg Oncol       Date:  1993-12       Impact factor: 4.424

8.  Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping.

Authors:  Yasuhiro Ito; Akira Miyauchi; Tomoo Jikuzono; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kiyoshi Ichihara; Kanji Kuma
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

9.  Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients.

Authors:  Marco Volante; Stefania Landolfi; Luigi Chiusa; Nicola Palestini; Manuela Motta; Alessandra Codegone; Bruno Torchio; Mauro G Papotti
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860

10.  Extranodal tumor extension to adjacent organs predicts a worse cause-specific survival in patients with papillary thyroid carcinoma.

Authors:  Yasuhiro Ito; Mitsuyoshi Hirokawa; Tomoo Jikuzono; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-06       Impact factor: 3.282

View more
  30 in total

1.  The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes.

Authors:  C Regalbuto; P Malandrino; F Frasca; G Pellegriti; R Le Moli; R Vigneri; V Pezzino
Journal:  J Endocrinol Invest       Date:  2012-07-09       Impact factor: 4.256

2.  Different CXCR4 expression according to various histologic subtype of papillary thyroid carcinoma.

Authors:  Dong Yeob Shin; Kwang Joon Kim; Cheol Ryong Ku; Mi Kyung Lee; Soo Il Jee; Woong Youn Chung; Eun Jig Lee
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

3.  Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Akira Yoshida
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

Review 4.  Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma.

Authors:  Tyler Janovitz; Justine A Barletta
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

5.  Clinical outcomes of patients with papillary thyroid carcinoma after the detection of distant recurrence.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya; Akira Miyauchi
Journal:  World J Surg       Date:  2010-10       Impact factor: 3.352

6.  EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer.

Authors:  Katsuhiko Masudo; Nobuyasu Suganuma; Hirotaka Nakayama; Takashi Oshima; Yasushi Rino; Hiroyuki Iwasaki; Kenichi Matsuzu; Kiminori Sugino; Koichi Ito; Tetsuo Kondo; Yoshiyasu Nakamura; Mitsuyo Yoshihara; Munetaka Masuda; Yohei Miyagi
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

7.  Thyroid cancers with benign-looking sonographic features have different lymph node metastatic risk and histologic subtypes according to nodule size.

Authors:  Dong Yeob Shin; Young Ki Lee; Kwang Joon Kim; Kyeong Hye Park; Sena Hwang; Se Hee Park; Eun-Kyung Kim; Hyeong Ju Kwon; Eun Jig Lee
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

8.  Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods.

Authors:  M Russo; P Malandrino; M Moleti; F Vermiglio; M A Violi; I Marturano; E Minaldi; R Vigneri; G Pellegriti; C Regalbuto
Journal:  J Endocrinol Invest       Date:  2017-05-20       Impact factor: 4.256

9.  Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in an iodine-sufficient country.

Authors:  Iwao Sugitani; Kazuhisa Toda; Noriko Yamamoto; Atsuhiko Sakamoto; Yoshihide Fujimoto
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

10.  Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours.

Authors:  Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.